Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Trading Down 10.1 %

Shares of Cyclacel Pharmaceuticals stock opened at $0.33 on Thursday. The firm has a market capitalization of $2.08 million, a P/E ratio of -0.04 and a beta of 0.35. The business’s fifty day simple moving average is $0.36 and its 200 day simple moving average is $0.64. Cyclacel Pharmaceuticals has a 12 month low of $0.30 and a 12 month high of $4.00.

Insider Buying and Selling

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of Cyclacel Pharmaceuticals stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total value of $5,838,864.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 23.97% of the stock is owned by insiders.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.